Abstract
In the present investigation chitosan microspheres loaded with flurbiprofen (FLB) were prepared by oil/oil emulsification method for colon specific drug delivery. FLB was entrapped in chitosan microspheres, following coating with Eudragit S-100 utilizing the benefits of pH dependent solubility of Eudragit S-100, so as to prevent the premature release of FLB in upper GIT. Different batches of FLB microspheres were prepared by varying FLB: chitosan ratio (1:1 to 1:4). The effect of chitosan concentration on size, entrapment efficiency, percent drug loading and degree of swelling was evaluated. DSC studies revealed the dispersion of FLB in the matrix of chitosan microspheres. SEM analysis indicated the nearly smooth surface and spherical shape of the prepared microspheres X-ray diffract gram of FLB microspheres showed less intense peaks as compared to free FLB. In vitro release studies of uncoated FLB- chitosan microspheres showed burst release in initial 4 h, while Eudragit S-100 coated microspheres prevented the premature release of FLB and showed controlled release for 12 h following Higuchi model, thus suitable for colon specific drug delivery.
Keywords: Colon specific delivery, Eudragit S-100, Flurbiprofen, Microspheres.
Current Drug Delivery
Title:Development of Colon Specific Microspheres of Flurbiprofen for Inflammatory Bowel Disease
Volume: 10 Issue: 5
Author(s): Rashmi Sareen, Nitin Jain and K. L. Dhar
Affiliation:
Keywords: Colon specific delivery, Eudragit S-100, Flurbiprofen, Microspheres.
Abstract: In the present investigation chitosan microspheres loaded with flurbiprofen (FLB) were prepared by oil/oil emulsification method for colon specific drug delivery. FLB was entrapped in chitosan microspheres, following coating with Eudragit S-100 utilizing the benefits of pH dependent solubility of Eudragit S-100, so as to prevent the premature release of FLB in upper GIT. Different batches of FLB microspheres were prepared by varying FLB: chitosan ratio (1:1 to 1:4). The effect of chitosan concentration on size, entrapment efficiency, percent drug loading and degree of swelling was evaluated. DSC studies revealed the dispersion of FLB in the matrix of chitosan microspheres. SEM analysis indicated the nearly smooth surface and spherical shape of the prepared microspheres X-ray diffract gram of FLB microspheres showed less intense peaks as compared to free FLB. In vitro release studies of uncoated FLB- chitosan microspheres showed burst release in initial 4 h, while Eudragit S-100 coated microspheres prevented the premature release of FLB and showed controlled release for 12 h following Higuchi model, thus suitable for colon specific drug delivery.
Export Options
About this article
Cite this article as:
Sareen Rashmi, Jain Nitin and Dhar L. K., Development of Colon Specific Microspheres of Flurbiprofen for Inflammatory Bowel Disease, Current Drug Delivery 2013; 10 (5) . https://dx.doi.org/10.2174/1567201811310050008
DOI https://dx.doi.org/10.2174/1567201811310050008 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Editorial
Current Medicinal Chemistry Gonadotropin-Releasing Hormone Receptor Signaling: Biased and Unbiased
Mini-Reviews in Medicinal Chemistry Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays
Current Pharmaceutical Design Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Editorial [Hot Topic: Overview of Antiangiogenic Therapies in Hematological Malignancies (Guest Editor: D. Ribatti)]
Current Cancer Drug Targets Immunotoxicity, Flow Cytometry, and Chemoinformatics: Review, Bibliometric Analysis, and New QSAR Model of Drug Effects Over Macrophages
Current Topics in Medicinal Chemistry Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Polyphenolic Coumpounds in Chemoprevention of Colon Cancer - Targets and Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors
Current Pharmaceutical Design The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science